- Home
- CTHR vs ONCO Comparison
CTHR vs ONCO Comparison
Compare CTHR & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTHR
- ONCO
- Stock Information
- Founded
- CTHR 1995
- ONCO 2018
- Country
- CTHR United States
- ONCO United States
- Employees
- CTHR N/A
- ONCO N/A
- Industry
- CTHR Consumer Specialties
- ONCO Biotechnology: Pharmaceutical Preparations
- Sector
- CTHR Consumer Discretionary
- ONCO Health Care
- Exchange
- CTHR Nasdaq
- ONCO Nasdaq
- Market Cap
- CTHR 4.1M
- ONCO 3.3M
- IPO Year
- CTHR 1997
- ONCO 2022
- Fundamental
- Price
- CTHR $1.45
- ONCO $0.42
- Analyst Decision
- CTHR
- ONCO
- Analyst Count
- CTHR 0
- ONCO 0
- Target Price
- CTHR N/A
- ONCO N/A
- AVG Volume (30 Days)
- CTHR 326.6K
- ONCO 282.9K
- Earning Date
- CTHR 02-11-2025
- ONCO 12-24-2024
- Dividend Yield
- CTHR N/A
- ONCO N/A
- EPS Growth
- CTHR N/A
- ONCO N/A
- EPS
- CTHR N/A
- ONCO N/A
- Revenue
- CTHR $23,684,860.00
- ONCO $1,870,605.00
- Revenue This Year
- CTHR $31.82
- ONCO N/A
- Revenue Next Year
- CTHR N/A
- ONCO N/A
- P/E Ratio
- CTHR N/A
- ONCO N/A
- Revenue Growth
- CTHR N/A
- ONCO N/A
- 52 Week Low
- CTHR $1.16
- ONCO $0.37
- 52 Week High
- CTHR $4.90
- ONCO $21.40
- Technical
- Relative Strength Index (RSI)
- CTHR 51.60
- ONCO 22.61
- Support Level
- CTHR $1.16
- ONCO $0.37
- Resistance Level
- CTHR $1.87
- ONCO $0.47
- Average True Range (ATR)
- CTHR 0.12
- ONCO 0.10
- MACD
- CTHR 0.04
- ONCO 0.10
- Stochastic Oscillator
- CTHR 36.62
- ONCO 15.28
About CTHR Charles & Colvard Ltd
Charles & Colvard Ltd manufactures, markets, and distributes finished jewellery which also includes moissanite gemstone in the jewellery market. The company sells jewels through two operating segments namely Online Channels segment and Traditional segment. It generates maximum revenue from the Online Channels segment. Online Channels segment which consists of e-commerce outlets including charlesandcolvard.com, moissaniteoutlet.com, third-party online marketplaces, drop-ship retail, and other pure-play, exclusively e-commerce outlets.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.